Industry
Biotechnology
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 10:16 am
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 11:37 am
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 3:49 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 8:25 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 5:11 pm
Portfolio Pulse from Benzinga Newsdesk
May 03, 2024 | 10:23 am
Portfolio Pulse from Benzinga Newsdesk
May 02, 2024 | 5:15 pm
Portfolio Pulse from Benzinga Newsdesk
May 02, 2024 | 12:14 pm
Portfolio Pulse from Benzinga Newsdesk
May 02, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
April 09, 2024 | 10:18 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.